BioAge CEO granted 330,000 stock options

Fortney Kristen reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Fortney Kristen reported acquisition or exercise transactions in this Form 4 filing.

BioAge Labs, Inc. director and Chief Executive Officer Kristen Fortney reported receiving a grant of stock options on February 17, 2026. The award covers 330,000 options with direct ownership. The options vest in equal monthly installments over four years, starting February 1, 2026, as long as she continues serving the company.

Insider Trade Summary

Grant/Award: 330,000 shares

Grant/Award 1 txn

Insider Fortney Kristen

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	330,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 330,000 contracts (Direct)

Footnotes (1)

1. F1. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BIOA report for Kristen Fortney on Form 4?

BIOA reported that CEO and director Kristen Fortney acquired a stock option grant. The award covers 330,000 derivative securities described as a “Stock Option (Right to Buy),” reflecting an equity-based compensation grant rather than an open-market purchase or sale of common shares.

How many stock options did BIOA CEO Kristen Fortney receive in this Form 4?

Kristen Fortney received a grant of 330,000 stock options. These options are reported as derivative securities, increasing her directly owned option holdings to a total of 330,000 following the transaction, according to the Form 4 insider reporting data for BioAge Labs, Inc. (BIOA).

What is the vesting schedule for Kristen Fortney’s BIOA stock option grant?

The option grant vests in 48 equal monthly installments. One forty-eighth vested on February 1, 2026, and each remaining tranche vests on the monthly anniversary of that date, conditioned on Kristen Fortney’s continued service to BioAge Labs, Inc. on each vesting date.

Is Kristen Fortney’s BIOA option transaction a buy or sell of shares?

The Form 4 classifies the transaction as an acquisition by grant or award. It is coded as a derivative security grant (transaction code “A”), not an open-market buy or sell of common stock, and reflects equity compensation issued directly to Kristen Fortney.

What type of security is reported in Kristen Fortney’s BIOA Form 4 filing?

The security reported is a derivative instrument labeled “Stock Option (Right to Buy).” This gives Kristen Fortney the right to purchase BioAge Labs, Inc. shares in the future, subject to the four-year monthly vesting schedule and her continued service to the company.

How is ownership characterized for Kristen Fortney’s BIOA stock option grant?

The Form 4 shows the 330,000 stock options as directly owned. The ownership code is “D,” indicating direct ownership by Kristen Fortney, with no footnote stating that another entity, trust, or related party holds voting or investment authority over the reported derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 04:36 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fortney Kristen

(Last) (First) (Middle)

C/O BIOAGE LABS, INC.

5885 HOLLIS STREET, SUITE 370

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$19.63	02/17/2026		A		330,000		(1)	02/16/2036	Common Stock	330,000	$0	330,000	D

Explanation of Responses:

1. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Dov A. Goldstein as attorney-in-fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.